Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Transplant results vary considerably from one organ to another. Lung transplantation has poorer long-term outcomes than other solid organ transplants, with a current median post-transplant survival of 6.0 years. Allograft rejection remains the leading cause of morbidity and mortality in all organ groups and is the leading cause of death, accounting for more than 40% of deaths beyond the first year after lung transplantation. Each dysfunctions impacts the fate of the graft and therefore the survival of the recipient. Their early and precise diagnosis is therefore a major issue. The identification of the pathophysiological mechanisms underlying these different subtypes of dysfunction (transcriptomics, polymorphism of target genes of the immune system or tissue repair, cell phenotyping) is an essential step. It can only be done on the basis of a collection of samples linked to a clinical database allowing to contextualize each sample.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 15
Healthy Volunteers: No
View:

• Men or women over 15 years of age

• Suffering from a lung condition requiring a transplant planned at Foch Hospital or being followed up at Foch Hospital following a lung transplant

• Have signed the informed consent form and for patients aged 15 to 18 years that the person(s) exercising parental authority has/have signed the informed consent.

• Be affiliated with a Health Insurance plan.

Locations
Other Locations
France
Roux
Recruiting
Suresnes
Contact Information
Primary
Antoine ROUX, Dr
a.roux@hopital-foch.com
0146252635
Backup
Elisabeth HULLIER-AMMAR, Dr
drci-promotion@hopital-foch.com
0146251175
Time Frame
Start Date: March 17, 2022
Estimated Completion Date: March 2037
Participants
Target number of participants: 900
Treatments
Other: Patients with lung disease requiring transplantation or who have undergone lung transplantation
There is no intervention to be administered.
Related Therapeutic Areas
Sponsors
Leads: Hopital Foch

This content was sourced from clinicaltrials.gov

Similar Clinical Trials